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Microsome biocolloids for rapid drug metabolism and inhibition
assessment by LC-MS
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Abstract
Rat liver microsomes attached to nanoparticles were used for LC-MS studies of CYP3A and 2E1
enzymes in metabolism of N-nitroso compounds. Using these biocolloids, turnover rates were
measured within 2 min. Inhibitor IC50 values for ketoconazole (KET) and 4-methylpyrazole (4-
MEP) were estimated.
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1. INTRODUCTION
Establishment of metabolism, cytotoxicity and enzyme inhibition is key for developing new
drugs [1-3]. In vitro metabolism and inhibition assessment often employs microsomes as
sources of multiple enzymes [2]. High throughput approaches are desirable for screening
[4-6]. While pure metabolic enzymes can be used, many are not commercially available,
necessitating laborious purification protocols. Hence, rapid, inexpensive methods employing
microsomes that are amenable to high throughput formats would be valuable.
Liver cytochrome P450 (CYP) enzymes play a central role in drug metabolism and
detoxification [7]. We recently developed assemblies of pure CYP enzymes with DNA on
silica nanoparticles for genotoxicity screening [8-11]. Enzyme reactions on the particles
produce metabolites that may react with DNA in the films, and metabolites and nucleobase
adducts are detected by LC-MS. In contrast, human and rat liver microsomes are
commercially available and are the source of many CYPs [12,13].
In this communication, we report assemblies of rat liver microsomes (RLM) and polyions in
stable films on silica nanoparticles (Scheme 1) and evaluate the metabolism and inhibition
of CYP3A and 2E1 enzymes. Attachment of RLMs to nanoparticles creates biocolloids with
the microsomes concentrated on their surfaces. CYPs in the microsomes were activated by
the natural NADPH-Cytochrome P450 reductase electron donation pathway [7]. N-
nitrosopyrrolidine (NPYR) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK))
(Scheme 2), were used as models because of their well known metabolic pathways along
with CYP-inhibitors [14,15] ketoconazole (KET) and 4-methylpyrazole (4-MEP). RLM-
biocolloids enabled metabolism and inhibition assays by LC-MS in microliter reaction
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volumes (250 μL) at incubation times as short as 15 s. This approach provides an accurate
method to establish metabolite structures, relative formation rates, and inhibition IC50
values, and is faster than using microsomes alone.
2. MATERIALS AND METHODS
2.1 Materials
Rat liver microsomes (RLM) were from BD Gentest. 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) and 4-hydroxy-1-(3-pyridyl)-butanone (4-HPB) were from
Toronto Research Chemicals. N-nitrosopyrrolidine (NPYR), 2-hydroxy tetrahydrofuran and
all other chemicals were from Sigma. Silica nanoparticles were from Polyscience, Inc (500
nm (±10%) dia., approx. 10% solids, d = 1.96 g/cm 3) and used after redispersing by
agitation.
2.2 Film assembly
Biocolloids were assembled by the electrostatic layer-by-layer (LbL) method [17]. Stock
silica nanoparticles dispersed in water (0.2 mL ~2 × 1011 beads) were added to
poly(ethyleneimine) (PEI, 1 mg mL−1, 50 mM NaCl) in a total volume of 1.0 mL for 20 min
to obtain steady state adsorption. The microspheres were removed from the dispersion by
centrifugation (2 min. at 8000 rpm), followed by resuspension in water and centrifugation
for three times. These nanoparticles were then resuspended in 50 μL of RLM dispersion at
4°C for 30 minutes followed by the same rinsing steps. The final film architecture was SiO2/
PEI/RLM (Scheme 1), and these nanoparticles are referred to as RLM biocolloids.
2.3 Metabolite Detection and Enzyme Inhibition
NAPDH generating system [13] (10 mM glucose-6-phosphate, 4 units glucose-6-phosphate
dehydrogenase, 10 mM MgCl2, 0.8 mM NADP+, 50 mM phosphate buffer, pH 7.0) was pre-
incubated at 37°C for 5 min. The RLM biocolloids above were resuspended in 50 mM
phosphate buffer (100 μL, pH 7.0) for 5 min at 37°C, then NNK or NPYR (1.0 mM) was
added. The reaction was initiated by combining 100 μL RLM biocolloid dispersion with 150
μL NADPH generating system. Total reaction volume was 250 μL. Reactions were run at
37°C and stopped by rapidly centrifuging the RLM biocolloids from the reaction solution.
For inhibition studies, ketoconazole (0-2μM) or 4-methylpyrazole (0-0.2μM) were pre-
incubated with the RLM biocolloids in pH 7 buffer (100μL) for 5 min before adding NPYR
or NNK (0.10, 1.0 mM). Metabolites from NNK and NPYR were identified using capLC-
MS analysis of the supernatant collected after centrifugation of the reaction mixture. Safety
note: NNK, NPYR and their metabolites are suspected carcinogens.
2.4 LC-MS/MS
The analytical column was Waters capillary Atlantis dC18 (150 mm, 300 μm I.D., 5 μm
particle size) with the same brand trapping column (23.5 mm). A similar procedure as
reported earlier was used [18]. Three 10 μL injections for each analysis were loaded into the
trapping column at flow rate of 4.25 μL min−1. Trapped metabolites were then back-flushed
from the trapping column onto the analytical column at 4.25 μL min−1 using elution
gradient: 10 mins – 10% B, 10 mins – 10% to 30% B, 10 mins – 30% B, 5 mins – 30% to 10
% B, 5 mins – 10% B. (A:10 mM acetate buffer pH 5.5, B: methanol). Electrospray
ionization mass spectrometry (ESIMS) employed a Micromass Quattro II operated in
positive ion mode (ESI+). Samples were analyzed by total ion scan (TIC) with cone voltage
15 V. Quantification of metabolites was done using calibration plots obtained by using
commercially available standards using concentrations ranging from 10 nM to 10 μM. Limit
Bajrami et al. Page 2













of quantitation was ~1 nM, reproducibility ±10% for replicate reaction runs, and sensitivity
based on LC integration was 95 counts/nM for both NNK and NPYR.
3. RESULTS
3.1. Metabolite Detection
The catalytic activity of CYPs −3A and −2E1 isozymes in the RLM-biocolloids for
metabolizing NNK and NPYR was evaluated in the absence and in the presence of inhibitors
and enzyme turnover rates were determined. Previous reports showed that CYP 2E1
metabolizes NPYR [19] and to small extent NNK [20]. CYP 3A isozymes are responsible
for metabolism of NNK [21]. The response from 2 min. incubation of RLM biocolloids with
NNK or NPYR in the presence of NADPH generating system was observed by capLC diode
array as shown in Fig. (1a,b).
In the samples subject to enzyme reactions, new peaks eluting before the respective
substrates is consistent with the formation of known hydroxylated metabolites [22]. MS
spectra from the TIC chromatograms are shown in the inset. The control chromatogram in
Fig. (1c) demonstrates the response when RLM biocolloids were incubated with NNK in the
absence of NADPH. The control experiment demonstrates that NADPH is necessary for the
activation of microsomal CYP leading to oxidation of the substrate. The molar amount of
metabolites generated vs. reaction times obtained via comparison to a standard plot is
illustrated in Fig. (1d). The turnover rate for NNK was 0.146 ± 0.015 pmol sec−1 mg RLM−1
and for NPYR was 0.116 ± 0.011 pmol sec−1 mg RLM−1 in the presence of RLM-
biocolloids were determined from the slope of the lines in Fig. (1d). For comparison, an
experiment with the exact same quantity of RLMs in solution (not fixed to nanoparticles)
was done under the same conditions, the turnover rate was calculated to be 0.0451 ± 0.005.
Activity toward NNK was approximately 60-70% smaller than with the RLM biocolloids.
(Fig. 1d). The RLM biocolloids retained ~80% activity when reused for NNK or NPYR
metabolite generation.
3.2. Enzyme Specific Inhibition
Metabolism of NNK was monitored in the presence of ketoconazole, a specific competitive
inhibitor of CYP 3A [14]; that of NPYR was monitored in the presence of 4-methylpyrazole,
a specific competitive inhibitor of CYP 2E1 [15]. Enzyme activity with and without the
inhibitors after 10 min incubation with RLM-bioreactors is shown in Fig. (2a). In the
presence of KET ~85% of enzyme activity toward NNK and 15-20% enzyme activity
toward NPYR were inhibited. Alternatively, exposure of RLM-biocolloids to 4MEP
inhibited approximately 90% of enzyme activity toward NPYR and 10-15% activity towards
NNK. The capLC chromatogram in Fig. (2b) illustrates the amount of metabolite generated
in the presence and absence of KET.
Inhibition reactions were done for different concentrations of inhibitor (KET or 4-MET)
while keeping the substrate concentration (NNK or NPYR) and incubation time constant
(Fig. 3). Results were used to determine IC50 values (Table 1) and confirm the predominant
CYP enzyme responsible for the metabolism. Comparison was made to control incubations
(0 mM inhibitor) and activity expressed as the percentage of enzyme activity remaining.
IC50 values were determined by linear interpolation (log. scale) [14].
4. DISCUSSION
Results above illustrate the ability of RLM biocolloids to generate metabolites in short
reaction times. Capillary LC-MS with on-line preconcentration permits detection of fmol
amounts of metabolites as reported previously [8,18].
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RLM-biocolloids provided ~60-70% larger rates of metabolism than with microsomes alone.
Immobilizing RLMs on nanoparticles concentrates large amounts of cytochrome P450
reductase (CPR) and CYPs in small reaction volumes. The improved rates could be
facilitated by cooperativity effects that are currently under further study.
Inhibition of KET and 4-MEP on enzyme activity of RLMs was characterized easily using
RLM-biocolloids. A significant decrease in NNK metabolite was observed in the presence
of KET compared to its absence (Fig. 2a,b) consistent with selective inhibition of CYP by
KET [14]. 4-MEP did not have a major effect on NNK metabolism (Fig. 2a). CYP 2E1
accounts for a small fraction of NNK metabolism in rat liver microsomes [23], and since it’s
not inhibited by KET, some 4-HPB (Scheme 2) is still being formed.
KET had a much smaller effect on NPYR metabolism, indicating that CYP 3A does not play
a significant role in NPYR metabolism. However, the introduction of 4-MEP decreased the
generation of NPYR metabolite (Fig. 2a), suggesting that CYP 2E1 plays a major role in
NPYR metabolism, consistent with literature [24]. Some 2-OH-THF (Scheme 2) is still
being formed after the introduction of 4-MEP suggesting that other microsomal CYPs are
involved in NPYR metabolism.
Evaluating inhibitor potency is a significant factor in elucidating drug-drug interactions and
can provide information for the therapeutic dose, as expressed by IC50 values. Generally
compounds with IC50 < 1 μM are considered potent inhibitors, those at 1-10 μM are
considered mild, and compounds with IC50 > 10 μM are considered weak inhibitors [25].
From Fig. 3, IC50 values using RLM biocolloids were 1.36 ± 0.21 μM for 4-MEP and 0.25
± 0.03 μM for KET. Based on these results, KET is a more potent inhibitor than 4-MEP,
which suggests that KET binds tightly with the CYP 3A enzymes, consistent with previous
reports [26].
In summary, rapid, accurate evaluation of metabolism and inhibition by chemical
compounds can be achieved using RLM biocolloid nanoreactors. The biocolloids are easily
removed by centrifugation for analysis of reaction solutions. If necessary, solvent extraction
can also be used to process products for analysis[8]. These novel microsome “nanoreactors”
are promising as the basis for eventual development of high throughput in vitro metabolism/
inhibition technology, e.g. by using them in microfluidic reactors coupled to appropriate LC-
MS configurations.
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capLC-photodiode array (PDA) chromatograms showing the generation of metabolite peaks
after 2 min. exposure of RLM biocolloids at pH 7.0 and 37° C to 1 mM (a) NNK or (b)
NPYR, and NAPDH generating system c) NNK exposed to RLM biocolloids in absence of
NADPH. Insets show MS spectra for metabolites 4-HPB and 2-OH-THF (Scheme 1) from
NNK and NPYR respectively; (d) Influence of reaction time on amount of HPB (dashed
line, closed circle) or 2-OH-THF (full line, open circle) formed in the presence of RLM-
biocolloids and HPB (dashed line, diamonds) formed with RLMs in solution.
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a) The effects of the specific inhibitors (KET and 4-MEP) on the catalytic activity of RLM-
biocolloids during the metabolism of NNK and NPYR. Data collected after 10 min.
incubation of RLM-biocolloids with respective N-nitrosamines and inhibitors, in the
presence of NADPH generating system. b) CapLC chromatograms illustrating the
metabolites formed with exposure of NNK to RLM films on silica nanospheres in the
presence of NAPDH generating system with and without KET, 10 minute incubation.
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Enzyme activity remaining with respect to control (no inhibitor) after 10 min incubation of
RLM biocolloids, NADPH generating system with: a) different concentrations of KET in the
presence of 0.1 mM NNK(open circle, dashed line) and 1.0mM NNK (closed squares, full
line) b) different concentrations of 4-MEP in the presence of 0.1 mM NPYR (half closed
squares, dashed line) and 1.0mM NPYR(closed circle, full line)
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Conceptual illustration of RLM film fabrication on silica nanospheres. Layer-by-layer
electrostatic assembly was used to first immobilize positively charged poly(ethylenimine)
PEI on the negative silica, then rat liver microsomes (RLM).
Bajrami et al. Page 9














NNK and NPYR metabolism featuring α-hydroxylation catalyzed by CYPs [16].
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Table 1
IC50 values of known specific inhibitors determined with RLM biocolloids
CYP Substrate/Inhibitor IC50 (μM)
2E1 NPYR/4-MEP 1.36
3A NNK/KET 0.25
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